

10/517581
DT05 Rec'd PCT/PTO 08 DEC 2004

"Express Mail" mailing label number EL 832893902 US

Date of Deposit DEC. 8, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Quentin Thomas

Quentin Thomas

Printed Name

Signature

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Ferritto, Rafael, et al.

For: PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONISTS

Docket No.: X-14844

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provides a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,

MaCharri Vordran-Jones

MaCharri Vordran-Jones, BS, MS, JD.
Attorney for Applicants
Registration No. 36,711
Telephone: 317-276-1665

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

December 8, 2004

FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-14844	Serial No
	Applicants	
	Filing Date	Group

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T ⁶
	CA	Beilstein Registry. No. 5961279 [abstract]	
	CB	Large, M.S. et al. 1983. 1-[(Substituted-amido)phenoxy]-3-[(substituted-amido)alkyl]amino]propan-2-ols. J. Med. Chem. 26(3): 352-357.	
	CC	Beilstein Registry. No. 3406655; Journal; Nametkin et al.; ZH. OБSHCH. KHM., 21, 1951, 2146-47.	
	CD	Beilstein Registry. No. 8569754 [abstract]	
	CE	Penning, T.H. et al. 2000. Structure-Activity Relationship Studies on 1-[2-(4-Phenylphenoxy)ethyl]pyrrolidine (SC-22716), a Potent Inhibitor of Leukotriene A ₄ (LTA ₄) Hydrolase. J. Med. Chem. 43(4): 721-35.	
	CF	Beilstein Registry. No. 5989230 [abstract]	
	CG	Barrie, S.E. et al. 1984. A Reappraisal of the Effect upon Thymidine Kinase of Thymidine Derivatives Carrying Large Groups at the 5'-Position. J. Med. Chem. 27(8): 1044-47.	
	CH	Beilstein Registry. No. 8227222 [abstract]	
	CI	Adamczyk, M. et al. 1999. Use of Lipase for Regioselective One Pot Amidation and Hydrolysis. Bioorg. Med. Chem. Lett. 9(2): 245-48.	
	CJ	Chem. Abst. No. 135:257231, Kadota, H. et al., <u>Preparation of catechol propionic acid derivatives as peroxisome proliferator-activated receptor (PPAR) .alpha. and .gamma. agonists</u> , application of JP 2001261612, September 26, 2001	
	CK	Wilson TM, et al. 2000. The PPARs: From Orphan Receptors to Drug Discovery. Journal of Medical Chemistry 43(4): 527-550.	
	CL	Etgen, GJ, et al. 2003. PPAR Ligands for Metabolic Disorders. Current Topics in Medicinal Chemistry 3(14): 1649-1661.	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.
Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sheet 1 of 2

FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-14844	Serial No
	Applicants	
	Filing Date	Group

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US 4,999,378	03-12-1991	Setsuro, et al.	
	AB	US 5,122,539	06-16-1992	Abraham, et al.	
	AC	US 5,378,716	01-03-1995	Hamanaka et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ - Kind Code ⁵ (if known)				
	BA	WO 00 63196 A	10-26-2000	PCT		
	BB	WO 03 051821 A	06-26-2003	PCT		
	BC	WO 03 051822 A	06-26-2003	PCT		
	BD	EP 0 558 062 A2	02-26-1993	EPO		
	BE	WO 02/14291 A1	02-21-2002	PCT		
	BF	WO 92/10468	06-25-1992	PCT		
	BG	WO 97/28115	08-07-1997	PCT		
	BH	WO 02/096893 A1	12-05-2002	PCT		
	BI	WO 01/40207 A1	06-07-2001	PCT		
	BJ	WO 99/11606	03-11-1999	PCT		
	BK	WO 96/38428	12-05-1996	PCT		
	BL	WO 03/048130 A2	06-12-2003	PCT		
	BM	WO 02/38553 A2	05-16-2002	PCT		
	BN	WO 01/16120 A1	03-08-2001	PCT		
	BO	WO 03/066581 A1	08-14-2003	PCT		